Over the past decade, considerable advances have been made in understanding genetic
influences on eating pathology. Eating disorders aggregate in families, and twin studies …

Interindividual differences in drug disposition are important causes for adverse drug
reactions and lack of drug response. The majority of phase I and phase II drug-metabolizing …

Abstract CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of
tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (eg …

Introduction: The frequency of CYP2D6 alleles, related to either a lack of or increased
enzymatic activity, which may lead to poor metabolism (PM) or ultrarapid metabolism (UM) …

Developing a more comprehensive understanding of the physiological underpinnings of
mental illness, precision medicine has the potential to revolutionize psychiatric care. With …

Introduction CYP2D6 contributes to the metabolism of approximately 20–25% of drugs.
However, CYP2D6 is highly polymorphic and different alleles can lead to impacts ranging …

Objectives: More than 40 drugs are available to treat affective disorders. Individual selection
of the optimal drug and dose is required to attain the highest possible efficacy and …

Abstract Treatment non-response and adverse reactions are common in patients receiving
antidepressants. Personalizing psychiatric treatment based on pharmacogenetic testing has …

Pharmacogenomics represents a potentially powerful enhancement to the current standard
of care for psychiatric patients. However, a variety of biological and technical challenges …

Abstract Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier
for the goal of global precision medicine. The RIBEF-CEIBA Network Consortium was …